Literature DB >> 25245010

Association between XRCC1 polymorphisms and glioma risk among Chinese population.

Jiang Li1, Qiang Qu, Jian Qu, Wei-Ming Luo, Shang-Yuan Wang, You-Zhi He, Qi-Shan Luo, Yu-Xia Xu, Yong-Fu Wang.   

Abstract

The pathogenesis of glioma remains largely unknown now. It has been suggested that the X-ray cross-complementing group 1 (XRCC1) gene may influence the capacity to repair DNA damage leading to an increased gliomas susceptibility. This study aimed to evaluate the relationship between XRCC1 polymorphisms and glioma risk. Genotypes were assessed in 368 Chinese glioma patients and 346 healthy controls. XRCC1 Arg194Trp (rs1799782), Arg280His (rs25489) and Arg399Gln (rs25487) and three additional polymorphisms were directly sequenced. The frequency of Arg280His A allele was significant lower in glioma group than in healthy controls [9.6 vs 16%, OR=0.60 (0.46-0.80), P<0.001]; the frequencies of GA or AA genotypes were different in two groups (16.6 vs 22.8%, 1.3 vs 4.7%). The frequency of Arg399Gln A allele was significant higher in glioma group than in healthy controls [38.7 vs 30.1%, OR=1.29 (1.11-1.49), P=0.001]; the frequencies of GA or AA genotypes were different in two groups (45.4 vs 38.2%, 16 vs 10.9%). This study demonstrates that the rs25489 (Arg280His) and Arg399Gln (rs25487) polymorphisms in XRCC1 gene might influence the risk of developing glioma in Chinese population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25245010     DOI: 10.1007/s12032-014-0186-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  26 in total

Review 1.  Malignant gliomas in adults.

Authors:  Patrick Y Wen; Santosh Kesari
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

2.  Assessment of the association between XRCC1 Arg399Gln polymorphism and glioma susceptibility.

Authors:  Weijie Zhu; Jie Yao; Yi Li; Bainan Xu
Journal:  Tumour Biol       Date:  2013-11-21

Review 3.  Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.

Authors:  Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

4.  Glioma risk associates with polymorphisms of DNA repair genes, XRCC1 and PARP1.

Authors:  Elif Yosunkaya; Baris Kucukyuruk; Ilhan Onaran; Cigdem B Gurel; Mustafa Uzan; Gonul Kanigur-Sultuybek
Journal:  Br J Neurosurg       Date:  2010-10       Impact factor: 1.596

5.  DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk.

Authors:  M C Stern; D M Umbach; C H van Gils; R M Lunn; J A Taylor
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-02       Impact factor: 4.254

6.  XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions.

Authors:  A E Vidal; S Boiteux; I D Hickson; J P Radicella
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

7.  Associations between three XRCC1 polymorphisms and glioma risk: a meta-analysis.

Authors:  Haijun Zhang; Hang Liu; Jennifer L Knauss
Journal:  Tumour Biol       Date:  2013-05-29

8.  Glioma risks associate with genetic polymorphisms of XRCC1 gene in Chinese population.

Authors:  Xingjun Feng; Guozhuan Miao; Yipeng Han; Yi Xu; Huayun Wu
Journal:  J Cell Biochem       Date:  2014-06       Impact factor: 4.429

9.  XRCC1 Arg280His polymorphism and glioma risk: A meta-analysis involving 1439 cases and 2564 controls.

Authors:  Liang Zhang; Yan Wang; Zhiqun Qiu; Jiaohua Luo; Ziyuan Zhou; Weiqun Shu
Journal:  Pak J Med Sci       Date:  2013-01       Impact factor: 1.088

10.  Association between the XRCC1 polymorphisms and glioma risk: a meta-analysis of case-control studies.

Authors:  Lei Jiang; Xiao Fang; Yi Bao; Jue-Yu Zhou; Xiao-Yan Shen; Mao-Hua Ding; Yi Chen; Guo-Han Hu; Yi-Cheng Lu
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

View more
  7 in total

Review 1.  Polymorphisms in DNA Repair Gene and Susceptibility to Glioma: A Systematic Review and Meta-Analysis Based on 33 Studies with 15 SNPs in 9 Genes.

Authors:  Kun Liu; Yugang Jiang
Journal:  Cell Mol Neurobiol       Date:  2016-04-07       Impact factor: 5.046

2.  Relationship between expression of XRCC1 and tumor proliferation, migration, invasion, and angiogenesis in glioma.

Authors:  Peng-Jin Mei; Jin Bai; Fa-An Miao; Zhong-Lin Li; Chen Chen; Jun-Nian Zheng; Yue-Chao Fan
Journal:  Invest New Drugs       Date:  2018-10-17       Impact factor: 3.850

3.  A Comprehensive Meta-analysis of Genetic Associations Between Key Polymorphic Loci in DNA Repair Genes and Glioma Risk.

Authors:  Ling Qi; Hong-Quan Yu; Yu Zhang; Li-Juan Ding; Dong-Hai Zhao; Peng Lv; Wei-Yao Wang; Ye Xu
Journal:  Mol Neurobiol       Date:  2016-02-03       Impact factor: 5.590

Review 4.  Association between X-ray repair cross-complementing group 1 gene polymorphisms and glioma risk: a systematic review and meta-analysis based on 22 case-control studies.

Authors:  Jiqiang Li; Qianxue Chen; Baohui Liu; Jian Yang; Lingmin Shao; Tingfeng Wu
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 5.  Screening for distress in patients with primary brain tumor using distress thermometer: a systematic review and meta-analysis.

Authors:  Fangkun Liu; Jing Huang; Liyang Zhang; Fan Fan; Jindong Chen; Kun Xia; Zhixiong Liu
Journal:  BMC Cancer       Date:  2018-02-02       Impact factor: 4.430

6.  Reappraisal of XRCC1 Arg194Trp polymorphism and glioma risk: a cumulative meta-analysis.

Authors:  Jun-Ti Lu; Ai-Ping Deng; Juan Song; Li Zhang; Jie Luo
Journal:  Oncotarget       Date:  2017-03-28

7.  The associations between common SNPs of EFEMP1 gene and glioma risk in Chinese population.

Authors:  Jun Hu; Dong Dong; Dandan Lu
Journal:  Onco Targets Ther       Date:  2017-11-06       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.